# Vinblastine +/- Bevacizumab in Children With Unresectable or Progressive Low Grade Glioma (LGG)

> **NCT02840409** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **The Hospital for Sick Children** · enrollment: 109 (actual)

## Conditions studied

- Low Grade Glioma

## Interventions

- **DRUG:** Vinblastine
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT02840409
- **Lead sponsor:** The Hospital for Sick Children
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2016-08-01
- **Primary completion:** 2024-07-31
- **Final completion:** 2026-08
- **Target enrollment:** 109 (ACTUAL)
- **Last updated:** 2024-01-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02840409

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02840409, "Vinblastine +/- Bevacizumab in Children With Unresectable or Progressive Low Grade Glioma (LGG)". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT02840409. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*